Nasal spray anesthesia to begin phase III trials
St. Renatus, the Colorado start-up founded to commercialize a new needle-free dental anesthetic, has secured up to $3.5 million from an angel investment group and will move forward with phase III clinical trials. The anesthetic, in the form of a nasal mist, is designed to anesthetize the maxillary arch. St. Renatus had a favorable end of phase II review with the U.S. Food and Drug Administration (FDA), with agreement that

